olmesartan medoxomil has been researched along with Disease Exacerbation in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, TX; Ding, A; Li, ZL; Yang, H; Zhang, H; Zhang, HT; Zhu, WP; Zhu, Y | 1 |
| Chin, HJ; Choi, BS; Kim, DK; Lee, SH; Lim, CS; Park, JH; Shin, SJ; Yu, MY | 1 |
| Aranda-Lara, P; Frutos-Sanz, MA; Goyache-Goñi, B; Hernández-Marrero, D; Reyes-Engels, A | 1 |
| Chen, YD; Jing, J; Tian, F; Wang, J; Yang, JJ; Zhang, T; Zhou, Y | 1 |
| Fukushima, R; Imai, H; Ishida, Y; Nakamoto, H; Suzuki, H; Yamanouchi, Y | 2 |
| Averill, DB; Brosnihan, KB; Chappell, MC; Ferrario, CM; Gallagher, PE | 1 |
| Egashira, K; Hiasa, K; Inoue, S; Ishibashi, M; Kitamoto, S; Ni, W; Nishida, K; Takeshita, A; Usui, M; Zhao, Q | 1 |
| Hori, M; Mano, T; Masuyama, T; Miwa, T; Nishikawa, N; Nishio, M; Ohtani, T; Sakata, Y; Yamamoto, K; Yoshida, J | 1 |
| Fujita, M; Hirata, A; Hori, M; Kitakaze, M; Liao, Y; Minamino, T; Nagamachi, Y; Nakatani, T; Ogawa, S; Okada, K; Ozawa, K; Takashima, S; Tomoike, H; Tsukamoto, O; Tsukamoto, Y; Yutani, C | 1 |
| Kohzuki, M; Wu, XM; Xu, HL; Yoshida, K | 1 |
| Kato, M; Koike, H; Mizuno, M; Sada, T | 1 |
2 trial(s) available for olmesartan medoxomil and Disease Exacerbation
| Article | Year |
|---|---|
Albuminuria during treatment with angiotensin type II receptor blocker is a predictor for GFR decline among non-diabetic hypertensive CKD patients.
Topics: Aged; Albuminuria; Angiotensin II Type 2 Receptor Blockers; Area Under Curve; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Male; Middle Aged; Olmesartan Medoxomil; Renal Insufficiency, Chronic; Risk Factors; ROC Curve | 2018 |
Efficacy study of olmesartan medoxomil on coronary atherosclerosis progression and epicardial adipose tissue volume reduction in patients with coronary atherosclerosis detected by coronary computed tomography angiography: study protocol for a randomized c
Topics: Adipose Tissue; Clinical Protocols; Coronary Angiography; Coronary Artery Disease; Disease Progression; Humans; Olmesartan Medoxomil; Pericardium; Prospective Studies; Sample Size; Tomography, X-Ray Computed | 2016 |
10 other study(ies) available for olmesartan medoxomil and Disease Exacerbation
| Article | Year |
|---|---|
Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Male; Mice; Olmesartan Medoxomil | 2019 |
The influence of renin-angiotensin system genotypes on the antiproteinuric response to high doses of olmesartan in non-diabetic proteinuric nephropathies.
Topics: Adult; Alleles; Angiotensin Receptor Antagonists; Antihypertensive Agents; Disease Progression; Drug Therapy, Combination; Female; Genotype; Humans; Hypertension; Imidazoles; Male; Middle Aged; Mutagenesis, Insertional; Mutation, Missense; Olmesartan Medoxomil; Point Mutation; Polymorphism, Genetic; Proteinuria; Renal Insufficiency, Chronic; Renin-Angiotensin System; Sequence Deletion; Tetrazoles | 2013 |
Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Dialysis Solutions; Disease Models, Animal; Disease Progression; Fibrosis; Hydrogen-Ion Concentration; Hypertension, Renovascular; Imidazoles; Male; Olmesartan Medoxomil; Peritoneal Dialysis; Peritoneal Diseases; Peritoneum; Rats; Rats, Wistar; Renin-Angiotensin System; Tetrazoles | 2008 |
Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. Lewis rat.
Topics: Angiotensin Receptor Antagonists; Animals; Animals, Congenic; Blood Pressure; Dinoprost; Disease Progression; Endothelin-1; Estradiol; F2-Isoprostanes; Female; Hypertension; Imidazoles; Male; Mice; Olmesartan Medoxomil; Ovariectomy; Rats; Rats, Inbred Lew; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Tetrazoles | 2003 |
Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Chemokine CCL2; Chemokines; Cytokines; Disease Progression; Gene Expression Regulation; Gene Targeting; Humans; Hyperlipoproteinemia Type II; Imidazoles; Inflammation; Inflammation Mediators; Injections, Intramuscular; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Olmesartan Medoxomil; Random Allocation; Recombinant Fusion Proteins; Sequence Deletion; Single-Blind Method; Tetrazoles | 2004 |
AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium-Binding Proteins; Calcium-Transporting ATPases; Diastole; Disease Progression; Drug Therapy, Combination; Extracellular Matrix; Heart Failure; Heart Ventricles; Hemodynamics; Hypertension; Imidazoles; Inflammation; Male; Olmesartan Medoxomil; Rats; Rats, Inbred Dahl; Reactive Oxygen Species; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Tetrazoles; Thiazepines; Ventricular Dysfunction, Left | 2004 |
Role of adhesion molecules in the progression of peritoneal sclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cell Adhesion Molecules; Dialysis Solutions; Disease Progression; Hydrogen-Ion Concentration; Imidazoles; Interleukin-6; Male; Olmesartan Medoxomil; Peritoneal Dialysis; Peritoneal Diseases; Peritoneum; Rats; Rats, Inbred WKY; Sclerosis; Tetrazoles | 2003 |
Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Valve Stenosis; Apoptosis; Cardiomegaly; Cells, Cultured; Disease Models, Animal; Disease Progression; Endoplasmic Reticulum; Gene Expression Regulation; Heart Failure; Humans; Imidazoles; Ligation; Male; Mice; Mice, Inbred C57BL; Molecular Chaperones; Myocytes, Cardiac; Natriuretic Peptide, Brain; Olmesartan Medoxomil; Rats; Rats, Inbred WKY; RNA, Messenger; Signal Transduction; Stress, Physiological; Tetrazoles; Thapsigargin; Tunicamycin | 2004 |
[Effects of CS-866, an angiotensin II receptor antagonist, in 5/6 nephrectomized spontaneously hypertensive rats].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Hypertension; Imidazoles; Kidney Failure, Chronic; Male; Nephrectomy; Olmesartan Medoxomil; Rats; Rats, Inbred SHR; Tetrazoles; Thiazepines | 2001 |
Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Cytoprotection; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Dose-Response Relationship, Drug; Imidazoles; Insulin; Kidney; Lipids; Male; Olmesartan Medoxomil; Proteinuria; Rats; Rats, Inbred Strains; Rats, Zucker; Receptor, Angiotensin, Type 1; Serum Albumin; Tetrazoles | 2002 |